YM155 (Sepantronium Bromide)

Catalog No.S1130

YM155 (Sepantronium Bromide) Chemical Structure

Molecular Weight(MW): 443.29

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 41 Publications

12 Customer Reviews

  • MM cell lines UM9 (left panel) or U266 (right panel) were cultured in presence or absence of accessory cells prior to incubation with CTLs alone, YM155 alone or the combination. Survival of UM9 and U266 MM cells was assessed by CS-BLI. Results show % lysis of MM cells after 24 hour incubation and are depicted for three doses.

    Clin Cancer Res 2013 19, 5591-601. YM155 (Sepantronium Bromide) purchased from Selleck.

    Dose response of ALL cell lines to YM155. Asynchronous populations of cells were treated with increasing doses of YM155 for 72 h. Then, viability was measured by MTS and normalized to no drug control. S.e.m. bars are inserted. Dotted line represents 50% viability.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Treatment of SUPB15 cells with imatinib or YM155. Top panel shows cells treated with siRNA in the presence of 500 nM imatinib. Cells were treated with siRNA, and then subsequently incubated in 500 nM imatinib for 96 h. Bottom panel shows the partial rescue of SUPB15 cells treated with 100 nM YM155 for 96 h. S.e.m. bars are inserted into each graph.

    Leukemia 2012 26, 623-632. YM155 (Sepantronium Bromide) purchased from Selleck.

    Inhibition of survivin expression restricts VZV repl ication and sprea d in vitro . ( A ) HEL F were infected w ith VZV-GFP in the presence of YM155 or DMSO, and infectious virus yields were determined at 48 hpi by titration on melanoma cells. ( B) VZV-GFP-infected HELF were treated with DMSO or YM155; plaques were detected by staining with anti-VZV IgG at 48 hpi. Plaque sizes were determined using ImageJ; the graph shows the mean size ?S EM o f 30 plaques . (C )Expression of VZV proteins was assessed in VZV-infected HELF lysat e s (24 hp i) treated with YM155 or DMSO.

    Proc Natl Acad Sci U S A 2012 109, 600-5. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Survivin inhibitor increased apoptosis in burn serum-stimulated cardiomyocytes. a YM155 increased apoptosis in burn serumstimulated cardiomyocytes in a concentration-dependent manner. Neonatal rat cardiomyocytes were treated with YM155 (3-300 nM at the indicated) for 2 h prior to stimulation burn serum for 12 h. The extent of DNA fragmentation was quantified using the Cell Death Detection ELISA. versus 0 nM YM155 plus stimulation with burn serum. b YM155 (100 nM) pretreatment increased the apoptosis production at 2 or 12 h after burn serum stimulation. c Representative blots of survivin and cleaved caspase-3 in YM155 (100 nM) pretreated cardiomyocytes at 2 and 12 h after burn serum stimulation. d Bar graphs show the relative proteins.

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

    Induction of cardiomyocytes apoptosis by survivin inhibitor in vivo. After YM155 was administered (5 mg/kg/day) for 5 days, the rats were exposed to a 40% TBSA burn (burn injury) or 25C water (sham) and killed 6 h after burn injury. The frozen sections of the ventricular tissues or whole cell lysates were prepared. Apoptotic staining was performed using the TUNEL method and immunostained using a-sarcomeric actin. The survivin and cleaved caspase-3 levels were measured by Western blot analysis. a Representative blots of survivin and cleaved caspase-3. b The statistical analysis of the relative proteins .c Figures are representative of two independent TUNEL experiments. Green fluorescence represents apoptotic cells, whereas red stain indicates staining for a-sarcomeric actin specific for cardiac myocytes. d Bar graph summarizes the counted apoptotic cells.

     

     

    Basic Res Cardiol 2011 106, 1207-1220. YM155 (Sepantronium Bromide) purchased from Selleck.

  • YM-155 sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 and B. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for up to 6 h. Then apoptotic cells were assessed as in Figure 2A and2B (representative apoptotic cells were marked with white arrows). C. LH86 and D. Huh7 cells were untreated or treated with ABT-263(1 μM), YM-155(1 μM) or combination of ABT-263(1 μM) and YM-155(1 μM) for 6 h. Cells with apoptotic nuclei were counted to determine cell death ratio (*p<0.05, **p<0.05). E. LH86 cells and F. Huh7 cells were treated as indicated and cell lysates were prepared and subjected to Western blotting.Apoptosis was evaluated through caspase 3 activation. b-actin was used as an equal protein loading control. G. LH86 cells grown in six-well plate were untreated (control) or treated with different conditions as indicated for 48 h. After rinsed with fresh culture medium for 3 times, cells were cultured for another two weeks. Cell colony formation assays were performed with crystal violet staining. H. colony number were counted to show combination treatment with ABT-263 and YM-155 resulted in reduction of clonogenesis (#p<0.05).

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

    Survivin down-regulation sensitizes ABT-263-induced apoptosis in HCC cells. A. LH86 cells were treated as indicated and cell lysates were prepared for Western blotting. Pro-apoptotic proteins: Bax, Bad, and Bak and anti-apoptotic proteins Bcl-xL and Mcl-1 were assessed with specific antibodies respectively. b-actin was detected and served as an equal protein loading control. B. LH86 cells were untreated or treated with ABT-263 (1 μM), YM-155 (1 μM) or combination of ABT-263 (1 μM) and YM155 (1 μM) for up to 6 h as indicated. Then cells were harvested and cell lysates were prepared for Western blotting. Anti-survivin and anti-Bcl-xL polyclonal antibodies were used to assess protein levels for survivin and Bcl-xL respectively. b-actin was used as an equal protein loading control. The band intensities of survivin, Bcl-xL, and b-actin was qualified with Image J software. C. LH86 cells were transiently transfected with synthesized random siRNA (control) or survivin specific siRNA duplexes, and 48 h posttransfection, cells were subjected to Western blotting analysis with anti-survivin polyclonal antibody. β-actin was used as an equal protein loading control. D. LH86 cells were transfected with synthesized random control siRNA or survivin specific siRNA, and 48 h post-transfection, cells were untreated or treated with ABT-263 (1 μM) for 24 h and then subjected to Hoechst staining to show apoptotic cells with condensed nuclei (representative apoptotic cells were marked with white arrows). E. LH86 cells were treated as in Figure 4D and apoptosis was measured as in Figure 2A. Statistical analysis was performed for apoptosis ratio by counting the number of cells with apoptotic nuclei (*p<0.05). F. LH86 cells treated as in Figure 4D were harvested and cell lysates were prepared and subjected to Western blotting. Apoptosis was determined through caspase 3 activation. β-actin was used as an equal protein loading control.

    PLoS One 2011 6, e21980. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Effects of YM155 on cell viability (A) and cell cycle (B), and on experiment of survivin mRNA (C) and protein (D) in the MiaPaCa-2 human pancreatic cancer cell line.

    Anticancer Res 2012 32, 1681-8. YM155 (Sepantronium Bromide) purchased from Selleck.

     

    IPF fibroblasts from 8 different patients were cultured to 60% confluence in DMEM supplemented with 10% fetal bovine serum and growth-arrested for 24 hours in serum-free DMEM prior to treatment for 16 hours with/without the Fas-activating antibody CH11 (FasL; 250 ng/ml) in the presence/absence of the survivin inhibitors CAY10625 (5 µM) or YM155 (10.0 µM), or with the survivin inhibitors alone. (a) Apoptosis was assessed using ELISA-based detection of histone associated DNA fragments. To allow relative comparisons of apoptosis across experiments, the data for each cell line is expressed as the percentage of the assay positive control that was included on each ELISA plate. The scatter plot shows the distribution of responses in individual cell lines along with the mean ± standard error for each treatment group. p = 0.038 overall (ANOVA). p = 0.027 for FasL compared to FasL/CAY10625, and p = 0.046 for FasL compared to FasL/YM155; (b) The correlation of apoptosis between IPF fibroblasts treated with FasL/CAY10625 and FasL/YM155. Each point represents a different IPF cell line. The Spearman correlation (r) = 0.95.
     

    Adv Biosci Biotechnol 2012 3, 657-664. YM155 (Sepantronium Bromide) purchased from Selleck.

  • Total RNA from livers of these mice were isolated from tissues using TRIZOL (Invitrogen). cDNA synthesis was performed with the M-MLV RTase cDNA Synthesis Kit (Promega). qRT-PCR reactions were performed using SYBR Green (Takara) on ABI 7500 Fast system. Expression levels of Survivin gene were measured by qRT-PCR in livers injected with 0.9% Nacl (91#,92#) or YM155 48 hours after DEN treatment.

    Lihua Min of Chinese Academy of Sciences. YM155 (Sepantronium Bromide) purchased from Selleck.

    Western blot analysis of Survivin. U-251 and PC-3 cell line was treated with 0-100nM YM-155.

     

     

    Dr. Chunrong Yu of RoswelI Park Cancer Institute. YM155 (Sepantronium Bromide) purchased from Selleck.

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 M3TsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqzZVI4OiCq NX\SO3RrTE2VTx?= MYPJR|UxRTBwMEC5JOKyKDBwMECwPUDPxE1? M{LIRVI2PjV7N{Ox
M-07e M2SyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi0fnQ4OiCq M{G2[GROW09? MXnJR|UxRTBwMESwJOKyKDBwMEGzJO69VQ>? MXmyOVY2QTd|MR?=
THP-1 NXnzZmN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHa[pM4OiCq NETiU45FVVOR NXHjbIlQUUN3ME2wMlA2OSEEsTCwMlAyOyEQvF2= NX;nUXk6OjV4NUm3N|E>
CMK MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LjSVczKGh? NY\kbmRrTE2VTx?= NH;We2VKSzVyPUCuNFU{KMLzIECuNFA6KM7:TR?= M4i3PVI2PjV7N{Ox
MV4-11 NW[1XVZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrXO|IhcA>? NYLjTXVMTE2VTx?= MofmTWM2OD1yLkC1OUDDuSByLkCyPEDPxE1? NV7LZYNKOjV4NUm3N|E>
AML-193 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLreHJDPzJiaB?= MWTEUXNQ NWPPRVh{UUN3ME2wMlQ3OiEEsTCwMlA3OCEQvF2= M{DNVVI2PjV7N{Ox
HL-60 NXjPcplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm3NkBp NFPDWpBFVVOR NFrRdm9KSzVyPUCuNFAyKMLzIECuNFAxOiEQvF2= M3L1eVI2PjV7N{Ox
ML-2 M{K1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\nNVczKGh? NF[x[29FVVOR NHzlVWJKSzVyPUCuNFA6KMLzIECuNFAzKM7:TR?= NVrMUVlqOjV4NUm3N|E>
OCI/AML3 NUCxR5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r2eVczKGh? NH;XeYtFVVOR NWnRRnZ6UUN3ME2wMlAyOSEEsTCwMlAxOiEQvF2= Mmn4NlU3PTl5M{G=
HEL M4e2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[xVlczKGh? NWfpcppSTE2VTx?= NXLEcGpFUUN3ME2wMlU2QSEEsTCwMlA{QCEQvF2= M3LzN|I2PjV7N{Ox
ME-1 NYCxdGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fHbVczKGh? NY\JeJB7TE2VTx?= MnrGTWM2OD1yLk[4OEDDuSByLkG3PUDPxE1? NUe1[nFmOjV4NUm3N|E>
THP-1 M4nEcWFxd3C2b4Ppd{BCe3OjeR?= MYqxxsDPxE1? M2DTPVczKGh? MkLQSG1UVw>? M{TwXolv\HWlZYOgZZBweHSxc3nz NVewfZRlOjV4NUm3N|E>
M-07e M2WxcWZ2dmO2aX;uJGF{e2G7 M1:0UlDjiJNzwrFOwG0> MlLlO|IhcA>? NF;sS25FVVOR NWP5NJJUcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MnXTNlU3PTl5M{G=
THP-1 NXXLblJOTnWwY4Tpc44hSXO|YYm= NVP2c|U{OOLCk{JCpO69VQ>? MmPWO|IhcA>? NYX4VG9MTE2VTx?= MknMbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NWLq[VFHOjV4NUm3N|E>
CMK M3zEUWZ2dmO2aX;uJGF{e2G7 NITpWZox6oDVMdMg{txO Mn7DO|IhcA>? NF:xVXVFVVOR M3nDTIlv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NHTLU5AzPTZ3OUezNS=>
AML-193 MYrGeY5kfGmxbjDBd5NigQ>? NVLYRXpjOOLCk{JCpO69VQ>? M4Dpc|czKGh? MkjLSG1UVw>? NIPTUVVqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHN2en[rdnnu MkfkNlU3PTl5M{G=
Kasumi-1 M{LKUmZ2dmO2aX;uJGF{e2G7 NUOxbpc3OOLCk{JCpO69VQ>? MnKzO|IhcA>? M3Hjc2ROW09? M4ix[Ilv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NUnr[XNqOjV4NUm3N|E>
MV4-11 M320O2Z2dmO2aX;uJGF{e2G7 NVLw[oNOOOLCk{JCpO69VQ>? NWjLSFk6PzJiaB?= M2C3[2ROW09? M4jXSolv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NUfUXnN2OjV4NUm3N|E>
MUG-Chor  M2Xz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;rOpNWOC13IN88US=> NXK1flRzOjRxNEigbC=> NIXqeItKSzVyPUeuNFXjiImwTTDmc5IhPDiq MXWyOVY1ODF6NR?=
U-CH1  M3nsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKwMVUh|ryP M1PYWlI1NzR6IHi= NILRNmZKSzVyPUmuNFPjiImwTTDmc5IhPDiq NIXYVpkzPTZ2MEG4OS=>
KATOIII NFvGXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyxNE8zOCCwTR?= Mm\IOFghcA>? NVXCOHA6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX;3eXN7OjV4M{WwOVU>
AGS  M2\D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXtNVAwOjBibl2= MYS0PEBp Mn7hbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3y0XlI2PjN3MEW1
SACC-83 MojkSpVv[3Srb36gRZN{[Xl? MoDPOUBvVQ>? MXO0PEBp MV\k[YNz\WG|ZYOgcpVkdGWjcjDlfJBz\XO|aX;uJI9nKEiLRj2x{tE> MV[yOVQ5PTZ|NR?=
INA-6 NVLvRXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPLZnF5OC13MECgcm0> M{i5S|Q5KGh? MmDEbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MUGyOVI6Pjl5OB?=
U-266 MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMVUxOCCwTR?= Ml;tOFghcA>? NYHTOXp4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEnVboQzPTJ7Nkm3PC=>
MOLP-8 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXibmpJOC13MECgcm0> NXmz[ZVWPDhiaB?= NH3ibZFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHvT[4UzPTJ7Nkm3PC=>
HG-1 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u2cFAuPTByIH7N NUTkZWU1PDhiaB?= NIC3[XVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEjlUZIzPTJ7Nkm3PC=>
NCI-H929 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrXNE02ODBibl2= NXfXXm5MPDhiaB?= NUnVXnRjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXqyOVI6Pjl5OB?=
OPM-2 NVzQb|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\FNE02ODBibl2= MoXxOFghcA>? NYm5W2p7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYjjXo9EOjV{OU[5O|g>
L-363 MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOwMVUxOCCwTR?= Mnz0OFghcA>? NFm1e2xqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{TwWFI2Ojl4OUe4
MOLP-2 NIrrN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLJbnBYOC13MECgcm0> NGDCfHQ1QCCq MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NH;2bFkzPTJ7Nkm3PC=>
KMS-12-BM NGTNSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLkNE02ODBibl2= NF7RNIQ1QCCq M{LkfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUeyOVI6Pjl5OB?=
SK-MM-2 M1:x[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjqNE02ODBibl2= MlfCOFghcA>? MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVmyOVI6Pjl5OB?=
U-266 M{PocmFxd3C2b4Ppd{BCe3OjeR?= NVjBfldoOC13MDDuUS=> NGfmepQzPCCq M4\DOYlv\HWlZYOgZZBweHSxc3nz M2LTOFI2Ojl4OUe4
INA-6  MULBdI9xfG:|aYOgRZN{[Xl? Mn7YNE02OCCwTR?= MlfQNlQhcA>? Moe2bY5lfWOnczDhdI9xfG:|aYO= NUfiRplWOjV{OU[5O|g>
MCF7 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\Md5I4OiCq NWXsWIJ2UUN3ME2xN{DDuSB4IH7N M1nmSlI2OjJyMkK1
MCF7-TamR6 M4f3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV2ySZVPPzJiaB?= MVnJR|UxRThiwsGgOkBvVQ>? M{PPZVI2OjJyMkK1
MCF7-TamR7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUG3NkBp NGHl[FRKSzVyPUigxtEhOyCwTR?= NEXmfJIzPTJ{MEKyOS=>
MCF7-TamR8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3faclczKGh? MVTJR|UxRTF3INMxJFYhdk1? NIXKcnYzPTJ{MEKyOS=>
MCF7-TamC3 NV;TVmxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPKbFA4OiCq NUXBXYdxUUN3ME22JOKyKDNibl2= NGnSN4kzPTJ{MEKyOS=>
MCF7-TamC6 NIHuXG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:3NkBp NEiwS5lKSzVyPU[gxtEhOC5zIH7N MmjKNlUzOjB{MkW=
MDA-MB-231 NVHv[|JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjJUIc4OiCq MVjJR|UxRTViwsGgNUBvVQ>? NYXJenRsOjV{MkCyNlU>
SK-BR-3 NF;xPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnuSFY4OiCq NGHOboZKSzVyPUegxtEhOC5|IH7N M3HTXVI2OjJyMkK1
Eca109 M1PrfWZ2dmO2aX;uJGF{e2G7 MXyxMVUxKG6P MnjhOFghcA>? NGrudIFFVVOR MV7zeZBxemW|c3XzJJN2en[rdnnuJIV5eHKnc4Ppc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MVyyOVE{QTN7NR?=
TE13 MXLGeY5kfGmxbjDBd5NigQ>? MmTDNU02OCCwTR?= NWH6cZZsPDhiaB?= Mmi3SG1UVw>? NHfEVVh{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MoT4NlUyOzl|OUW=
Eca109 NFfEbYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV65c5pmOC1zMECgcm0> M{[ySlI1NzR6IHi= M2D2dWROW09? NIPpRWdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV:yOVE{QTN7NR?=
TE13 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G0TFAuOTByIH7N MlT6NlQwPDhiaB?= NWDiN|FlTE2VTx?= Mn3j[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUHzV5IyOjVzM{mzPVU>
MT-3 MYfLbY5ie2ViQYPzZZk> MlXvO|IhcA>? Mny1SG1UVw>? NGHiN45KSzVyPUKuPFYhyrFiMD61OEBvVSCob4KgSHI1KGW6cILld5Nqd25? NHztfYMzPDh4NkW4OS=>
MDA-MB-468 MknHT4lv[XOnIFHzd4F6 NVrFbWJJPzJiaB?= MYTEUXNQ MV3JR|UxRTBwMUGgxtEhOC5yMTDuUUBnd3JiRGK0JIV5eHKnc4Ppc44> M4TIXFI1QDZ4NUi1
SUM-159 MmjGT4lv[XOnIFHzd4F6 MmPqO|IhcA>? MWLEUXNQ NHfQblBKSzVyPUGuO|IhyrFiMD6zN{BvVSCob4KgSHI1KGW6cILld5Nqd25? MnjENlQ5PjZ3OEW=
MT-3 NVzTbFNGU2mwYYPlJGF{e2G7 MWq3NkBp MYXEUXNQ M{i5TmlEPTB;NUSuNVEhyrFiND6zNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MoLSNlQ5PjZ3OEW=
MDA-MB-468 M4DiWGtqdmG|ZTDBd5NigQ>? MVG3NkBp NVzOWpVDTE2VTx?= MYnJR|UxRTBwMEegxtEhOC5yMjDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> NEHNN5UzPDh4NkW4OS=>
SUM-159 M2G2W2tqdmG|ZTDBd5NigQ>? NEj0XIE4OiCq M2LYOWROW09? MX7JR|UxRTZ7LkSgxtEhPC5{MzDuUUBnd3JiRGK1JIV5eHKnc4Ppc44> NIftSmkzPDh4NkW4OS=>
MT-3 + NAC M{jw[mtqdmG|ZTDBd5NigQ>? NIH5[2o4OiCq Mlu5SG1UVw>? MnT5TWM2OD13Nj6yJOKyKDJwMEegcm0h\m:{IFTSOUBmgHC{ZYPzbY9v MljwNlQ5PjZ3OEW=
MT-3 + SB203580 NV32e|c4U2mwYYPlJGF{e2G7 MlLXO|IhcA>? M2HoN2ROW09? M1j6O2lEPTB;M{iuOFEhyrFiNT6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? MUOyOFg3PjV6NR?=
DB M3\rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7qT4FFOTBibl2= NYXEWnRCOjRiaB?= NYfzbY5{TE2VTx?= M2LJdIlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> NF:3[mwzPDR6NkW5OS=>
SU-DHL-8 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2naSlExKG6P MV[yOEBp M4fvPWROW09? NIHPb|RqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> M1OzU|I1PDh4NUm1
WSU-DLCL2 M{nKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX3NIxXOTBibl2= NWSz[oJ1OjRiaB?= MXXEUXNQ MlHGbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NEXKRYszPDR6NkW5OS=>
ACC-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES4OGUxNTFyMDDuUS=> MWGyOEBp MlrHbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MliyNlQ{PzB7OUW=
ACC-2 Mn7QRZBweHSxc3nzJGF{e2G7 MWSwMVIxKG6P MU[yOEBp Mor2bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFrDNXczPDN5MEm5OS=>
ACC-2 M2rtVGZ2dmO2aX;uJGF{e2G7 NWW0V25GOC1{MDDuUS=> NH;DZVUzPCCq NVXIb3NicW6lcnXhd4V{KHSqZTDjc453\XK|aX;uJI9nKEyFM1mgeI8hVEN|SVm= NVuwS2RPOjR|N{C5PVU>
BFTC905 M{W4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP0RXF[OC1zMECwJI5O NGW4NFU1QCCqwrC= NYjrOlhMTE2VTx?= NVnadVJNUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoTsNlQzQTd4NES=
T24 M4n0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljuNE0yODByIH7N MXW0PEBpyqB? MmPLSG1UVw>? NELOe2ZKSzVyPUKwJI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1rl[lI1Ojl5NkS0
TSGH8301  NF\ydG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5NE0yODByIH7N M{CyfFQ5KGkEoB?= NGTLcmxFVVOR MVvJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2Ox[VI1Ojl5NkS0
BFTC909 M2XJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TwXlAuOTByMDDuUS=> MlG5OFghcMLi M2LiVGROW09? M4nLZWlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2HDS|I1Ojl5NkS0
BFTC905 NEfIUYlCeG:ydH;zbZMhSXO|YYm= NYq2ZXFGOjBibl2= MXu0PEBp NUnhd5ZRTE2VTx?= M4DmfIlv\HWlZYOgZZBweHSxc3nz NVPWVnE3OjR{OUe2OFQ>
BFTC905 MlXVSpVv[3Srb36gRZN{[Xl? M{HifVIxKG6P M4PZO|Q5KGh? NH3FXIZFVVOR M3L0e4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzOELVnJ NFrObWQzPDJ7N{[0OC=>
A2780p NWXDfGpmTnWwY4Tpc44hSXO|YYm= NVXweI9OOC1zMECgcm0> NFHqSnczPCCq M37iS2ROW09? NHz4UWxqdmS3Y3XzJHN2en[rdnnuJIRwf26{ZXf1cIF1cW:wwrC= NUL0T4RuOjR{NkK4O|U>
A2780cis MnrOSpVv[3Srb36gRZN{[Xl? M{G5ZlAuOTByIH7N NXnac|dKOjRiaB?= NGPkcWZFVVOR MoLVbY5lfWOnczDTeZJ3cX[rbjDkc5dvemWpdXzheIlwdsLi MmT0NlQzPjJ6N{W=
A2780p NUfFVHZ1SXCxcITvd4l{KEG|c3H5 NYTlO4xtPS1zMECgcm0> NETLU|EzPC92ODDo MoXFSG1UVw>? MVrpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MW[yOFI3Ojh5NR?=
A2780cis NGT0b5hCeG:ydH;zbZMhSXO|YYm= MUe1MVExOCCwTR?= MWiyOE81QCCq MkDQSG1UVw>? MX;pcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MXSyOFI3Ojh5NR?=
SH-SY5Y M4XLO2Fxd3C2b4Ppd{BCe3OjeR?= M1OzSlEwOTBxMUCwJOK2VQ>? M2\UdlczKGh? M4LlcWROW09? M4WxdIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGTO[2MzPDJ3NEW2NC=>
HL-60 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHzO|LDqGh? NIK5UZlFVVOR NHLZSYtKSzVyPUCuN{BvVQ>? M3j3OVI{PjF6OE[y
U937  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTMVY04OsLiaB?= NYPyeY9nTE2VTx?= NYjMe21PUUN3ME2wMlghdk1? NVzKTFNyOjN4MUi4OlI>
HL-60  NVW0TXg{TnWwY4Tpc44hSXO|YYm= MV[xxsDPxE1? MWO2M|EzNzJ2IHi= MW\EUXNQ NVHMeY8xcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> MmfmNlM3OTh6NkK=
U937  MoTkSpVv[3Srb36gRZN{[Xl? M{\HdVHDqM7:TR?= NVzUSoxQPi9zMj:yOEBp NXn0XlhnTE2VTx?= NHzvOI9qdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kB{fXK4aY\pci=> MUOyN|YyQDh4Mh?=
HL-60 NYLDbZVNSXCxcITvd4l{KEG|c3H5 NHm0NHgxNjFxMTFOwG0> Mn;nPEBp NVHnSlB1TE2VTx?= NVnaVWdFcW6mdXPld{BieG:ydH;zbZM> MWOyN|YyQDh4Mh?=
Sk-NEP-1  M4W4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLrc|A6OS1zMECwNEBvVQ>? NGfhemYzPCCq NEWxbHZFVVOR MWLJR|UxRTFyMDDuUS=> MnHuNlMzPjd4OUm=
SK-NEP-1  NUL0TWgzSXCxcITvd4l{KEG|c3H5 MYG1NE8yODBibl2= M175clEzNzJ2IHi= NXrUfZBTTE2VTx?= M4KwTIlv\HWlZYOgZZBweHSxc3nz M3X2OlI{OjZ5Nkm5
TC-32 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWwNE4yNTFyMECgcm0> NXrHbIlUTUN3ME2zMlAhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MoLyNlI6PjF5NkO=
TC-71 MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jr[lAvOS1zMECwJI5O MVrFR|UxRTVwNzDuUUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4rlO|IzQTZzN{[z
SK-ES-1 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqwMlEuOTByMDDuUS=> M1XPTGVEPTB;Mj64JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFjob|AzOjl4MUe2Ny=>
RD-ES MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUiybmVqOC5zLUGwNFAhdk1? NUTWUWtQTUN3ME22MlIhdk1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlTrNlI6PjF5NkO=
HEK293 NHGwcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:wMlEuOTByMDDuUS=> MVjFR|UxRTJ|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4nXW|IzQTZzN{[z
M059J M3XKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XjfFAuPTBibl2= NGLJTJg1QCCq NWTWPJFqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX6yNlc4ODFzMB?=
M059K NHLjZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOwMVUxKG6P MkDXOFghcA>? NX3XPYx1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFi2[ZozOjd5MEGxNC=>
M059J MmDXRZBweHSxc3nzJGF{e2G7 NGLUS3k{OCCwTR?= NVrySFV2OjRiaB?= Mmq1bY5lfWOnczDhdI9xfG:|aYO= MlzuNlI4PzBzMUC=
M059K MnflRZBweHSxc3nzJGF{e2G7 M1raO|MxKG6P NF\DNGYzPCCq MX7pcoR2[2W|IHHwc5B1d3Orcx?= MnvCNlI4PzBzMUC=
PANC-1 NH74bYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXCSlIxNjBzLUGwNFAhdk1? NUjPWWF2PDhiaB?= M3:0cmlEPTB;Mz62PUBvVQ>? M3jLV|IzPzJ|OEex
MIAPaCa-2 NWWzTY1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\Ifm8xNjBzLUGwNFAhdk1? M2fKUFQ5KGh? NVfFRW44UUN3ME2yPU4{PiCwTR?= MY[yNlczOzh5MR?=
BxPC-3 NV;Dc3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMlAyNTFyMECgcm0> NYfNOHhIPDhiaB?= NHXEVpFKSzVyPUOwMlI3KG6P NH2wOFEzOjd{M{i3NS=>
PANC-1 MYTGeY5kfGmxbjDBd5NigQ>? NUGzcFJLOC1zMECwJI5O NILGeVczPCCq NGfFT|NqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> NGrF[YszOjd{M{i3NS=>
MIAPaCa-2 MojnSpVv[3Srb36gRZN{[Xl? NYG5SYNKOC1zMECwJI5O NG\HeW4zPCCq MV;pcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= MkLFNlI4OjN6N{G=
BxPC-3 NH;kPFdHfW6ldHnvckBCe3OjeR?= MXGwMVExODBibl2= NFT3UJIzPCCq NH65UGZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> MX6yNlczOzh5MR?=
RPMI-7951 NFPWeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q5[mdKPTB;Mz6yJI5O NVrVN2JbOjF5M{e1NFI>
SK-MEL-5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\kemhqT0l3ME20MlIhdk1? MoT0NlE4Ozd3MEK=
A375 M3;Vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHHTVUxRTZwMzDuUS=> MUKyNVc{PzVyMh?=
SK-MEL-28 NF\KRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrHTVUxRTdwNjDuUS=> M1PSZVIyPzN5NUCy
SK-MEL-2 NUXzVlE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInKXnZIUTVyPUGxJI5O MXKyNVc{PzVyMh?=
DB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljYOFjDqGh? M3LxdWdKPTB;Mz61JI5O NHrZbnYzOTJ|N{WwPC=>
Pfeiffer NVPh[HBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljyOFjDqGh? M1zTZWdKPTB;Mz65JI5O Mk\uNlEzOzd3MEi=
SU-DHL-5 M13HNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33MUFQ5yqCq NVXtTWp7T0l3ME2wMlI{KG6P MWSyNVI{PzVyOB?=
SU-DHL-8 NWjnXG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f4NVQ5yqCq NWDTRXY4T0l3ME2xMlQhdk1? MlLFNlEzOzd3MEi=
WSU-DLCL-2 NHfnWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorvOFjDqGh? NUPN[XQ{T0l3ME2xMlQhdk1? NYL3bFNrOjF{M{e1NFg>

... Click to View More Cell Line Experimental Data

In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

+ Expand
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Formulation: Dissolved and diluted in saline immediately before administration
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01100931 Completed NSCLC|Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 2010 Phase 1|Phase 2
NCT01038804 Completed Breast Cancer Astellas Pharma Inc December 2009 Phase 2
NCT01023386 Completed Cancer Astellas Pharma Inc November 2009 Phase 1
NCT01009775 Completed Melanoma Astellas Pharma Inc November 2009 Phase 2
NCT01007292 Completed Non-Hodgkin''s Lymphoma Astellas Pharma Inc November 2009 Phase 2
NCT00498914 Terminated Lymphoma Large-Cell Diffuse|Lymphoma B-Cell Refractory Astellas Pharma Inc June 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID